A DEA administrative judge paused the cannabis rescheduling hearing to consider a GAO watchdog report on process gaps. A DEA response is due by October 13, adding delay and uncertainty.

As microdosing goes mainstream, here’s how to decide between a solo approach or working with a coach—plus DMV-specific considerations and compliance tips.

A practical, ethical guide to talking with parents about psilocybin—what to say, how to support them, and what DC, Maryland, and Virginia residents should know.

California approved two cannabis bills focused on product testing, tracking, consumer information and cannabinoid content. Here’s what changed, how it may ripple beyond CA, and what DMV readers should watch next.

After pushback from operators and advisors, Oregon health officials shelved a proposal to hike psilocybin license fees. Here’s what changed, why it matters, and what to watch next.

California’s cannabis tax haul hit nearly $8.4B since 2018. Here’s how that scale shapes delivery models, investor strategy, and what DMV operators should plan for next.

Fresh Census-tracked excise taxes crossed $3.55B across 30 states and DC. Here’s how that trend shapes delivery business models, investor strategy, and DMV opportunities.

Federal health officials and clinical experts met in Silver Spring to establish safety, credentialing, and access standards for psychedelic medicines.

A new GAO report says DEA and FDA lack clear drug-scheduling procedures just as an ALJ reviews moving cannabis to Schedule III and court fights continue.

Psychedelic Alpha has introduced The Psychedelic News Feed Podcast, creating a new way to follow psychedelics developments. Here’s why DMV readers should care.

Marijuana Moment reports over $500K in alcohol-linked donations to Ken Paxton as his office targets local decrim policies and bans hemp-derived THC products.

DEA issued a scheduling order for five tryptamines as FDA momentum grows, including breakthrough status for a 4‑OH‑DiPT drug candidate aimed at postpartum depression.

A new federal court ruling, recalls, and retail trends are shifting risk and opportunity for cannabis delivery apps, couriers, and investors across the DMV.

NORML reports the latest CDC findings show high school marijuana use at a historic low — a data point likely to shape youth access rules, delivery compliance, and policy debates in the DMV.

Bipartisan federal moves and a new Louisiana pilot are reshaping psychedelic therapy research. Here’s how it intersects with dc cannabis research, patient access, and safety.

A new Psychedelic Alpha podcast surveys D.C.’s psychedelic moment, the FDA’s evolving medical framework, and New Zealand’s MDMA prescribers—here’s why the DMV should care.

A small Johns Hopkins pilot gave two psilocybin doses to 20 adults with chronic Lyme symptoms. Participants reported improved sleep and quality of life, and a 40% symptom drop at six months.

Dutch officials issued a Red Alert for two-toned Trump-shaped pills that look like ecstasy but contain high-dose PMMA with a slower onset and higher overdose risk.

From West Virginia to Hawaii, lawmakers are prepping for FDA-approved psilocybin drugs—not legalizing mushrooms. Here’s what’s moving, who’s behind it, and how it could affect DMV residents.

Reporting from three men serving decades to life shows how re-entry-only programming sidelines lifers, harms safety, and erodes health access inside U.S. prisons.